Effects of Esketamine on Postpartum Depression

This interventional trial (n=500) aims to explore the effects of different concentrations of esketamine on postpartum depression (PPD) following cesarean section.

Pregnant women undergoing cesarean section at Qinghai Red Cross Hospital between February 2022 and September 2022 were selected. They were randomly divided into five groups, including a control group and four esketamine dose groups (E0.2, E0.4, E0.6, E0.8).

The study evaluates postoperative psychological status and analgesic effects to determine the optimal Esketamine dosage for depression and pain relief. Patients receive postoperative intravenous analgesia pump formulations, and their psychological status and analgesic effects are measured using the Edinburgh Postpartum Depression Scale (EPDS) score and other scales.

The study, sponsored by Qinghai University, was expected to be completed by June 2023.

Trial Details

Different concentrations of Esketamine were used after cesarean section. Through the evaluation of postoperative psychological status and analgesic effect, the optimal dosage of Esketamine to exert the effects of depression and analgesia was analyzed.

NCT Number NCT05229913

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.